Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
BUSINESS - CERVICAL CANCER DETECTION

Cervical Cancer detector may improve on Pap Smears

 

BY OUR PHARMA  CORRESPONDENT

CHERRY HILL, N.J., June 28 /PRNewswire/ -- Physicians may soon give their patients immediate and accurate results during a routine pap smear exam designed to screen for any abnormalities in the cervix.

A medical device in development may be able to identify molecular change in the cervix and optically assess if the cervix is normal, malignant, dysplastic (pre-cancer) or benign.

Mediscience Technology Corp. in collaboration with Dr. Robert Alfano and his team at the City College of New York (CUNY) have developed the Cancer Detection Ratiometer (CD-R), which is expected to enter clinical trials (http://www.medisciencetech.com/).

"Rapid results are important because, although cervical cancer develops slowly, the earlier cancerous or pre-cancerous cervical conditions are detected, the greater the likelihood for a cure, " says Dr. Stephane Lubicz, a gynecological oncologist based in New York. "Many things can interfere with accurate pap test results; among them not enough cells on the slide or improperly preparing the smear."

The CD-R can optically assess cervical tissue using auto-florescent lighting at pre-established wavelengths to diagnose the state of the cervix without removing it from the body. The technology immediately reports to the physician any abnormal cell activity on the CRT screen. This process may eventually eliminate the long waiting for pap smear results.

"The CD-Ratiometer has shown sensitivity and specificity equal or greater than ninety percent in vitro studies. The technology will not give false results, and so far has no-known serious side effects," says Dr. Lubicz.

The American Cancer Society (ACS) estimates that 10,500 cases of invasive cervical cancer will be diagnosed in the United States in 2005, and 3,900 women will die from the disease. The five-year survival rate for invasive cervical cancer that is caught at its earliest stage is nearly 100 percent.

Cervical cancer rates are higher among older women. Half of women diagnosed with cervical cancer are between the ages of 35 and 55.

RELATED CANCER STORIES

All cancer headlines

Drug for advanced colorectal cancer gets marketing nod in Canada
18 September,2005

Advanced prostate cancer therapy Provenge seeks marketing nod in US
18 September,2005

New kidney cancer drug seeks EU nod
13 September,2005

Breast cancer drug Aromasin approved in Europe: Pfizer  
15 Sep, 2005

Lung cancer vaccine trials promising: Introgen 
13 September,2005 

Rituxan, cancer drug can treat rheumatoid arthritis
2 September, 2005

Novartisí drug for breast cancer recurrence to be given priority review in US
31 August, 2005

New cancer combo therapy results positive: OXiGENE
25 August, 2005 

Cell Therapeutics to seek approval for lung cancer therapy in US and Europe
25 August, 2005

Aspirin stops colon cancer, but may trigger bleeding
24 August, 2005

Skin disease drug turns into anti-tumor therapy for cancer
22 August, 2005

"Breast cancer chances higher due to fried chips"
22 August, 2005

Pfizer files NDA for Sutent in US
13th August,2005

Alcohol linked cancers: Acetaldehyde in spot light
10 August, 2005

Chemokine gets US patent for novel cancer drug
20 June, 2005

Prohibitive costs mar cancer therapy
15 July, 2005

Viruses may help cure cancer by killing cancer cells
CALGARY, Alberta, June 28

Cervical Cancer detector may improve on Pap Smears
CHERRY HILL, N.J., June 28 

Novartis has better breast cancer treatment
Toronto, Ontario, April 11, 2005

Roche, Novartis lead on novel cancer therapies
23 July, 2005

Pfizer's investigational drug reduces tumor growth
14 May, 2005

   Pharma Home

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us